AAPL294.30-2.71 (-0.91%) ▼|ABBV234.76+4.75 (+2.07%) ▲|ABT90.53+2.70 (+3.07%) ▲|ACN127.01+2.18 (+1.75%) ▲|ADBE197.43+2.53 (+1.30%) ▲|AMAT585.88-54.30 (-8.48%) ▼|AMD519.85-31.78 (-5.76%) ▼|AMGN347.01+2.29 (+0.66%) ▲|AMT179.38+2.95 (+1.67%) ▲|AMZN234.11+1.32 (+0.57%) ▲|AVGO380.15-11.98 (-3.06%) ▼|AXP337.78-0.29 (-0.09%) ▼|BA216.71-4.12 (-1.87%) ▼|BAC57.91+0.54 (+0.94%) ▲|BKNG168.94+1.17 (+0.70%) ▲|BLK1,015.33-36.41 (-3.46%) ▼|BMY55.53+0.83 (+1.52%) ▲|BNY147.29+0.85 (+0.58%) ▲|BRK-B492.81+4.12 (+0.84%) ▲|C144.97-0.70 (-0.48%) ▼|CAT984.24-38.04 (-3.72%) ▼|CL91.43+2.76 (+3.11%) ▲|CMCSA22.80+0.48 (+2.15%) ▲|COF197.81-2.89 (-1.44%) ▼|COP109.97+0.27 (+0.25%) ▲|COST957.68+6.33 (+0.67%) ▲|CRM153.42+3.30 (+2.20%) ▲|CSCO121.15-0.38 (-0.31%) ▼|CVS101.57+0.27 (+0.27%) ▲|CVX175.98+0.92 (+0.53%) ▲|DE591.94-6.65 (-1.11%) ▼|DHR178.97+0.78 (+0.44%) ▲|DIS103.53+1.08 (+1.05%) ▲|DUK125.05+1.53 (+1.24%) ▲|EMR143.14-7.07 (-4.71%) ▼|FDX317.24-11.54 (-3.51%) ▼|GD350.34+6.98 (+2.03%) ▲|GE356.47+1.35 (+0.38%) ▲|GEV1,034.98-92.61 (-8.21%) ▼|GILD125.05+0.18 (+0.14%) ▲|GM78.95-1.48 (-1.84%) ▼|GOOG346.08-2.70 (-0.77%) ▼|GOOGL346.13-3.43 (-0.98%) ▼|GS1,094.44-11.93 (-1.08%) ▼|HD324.45-2.17 (-0.66%) ▼|HON222.37-5.74 (-2.52%) ▼|IBM264.94+12.72 (+5.04%) ▲|INTC132.28-8.66 (-6.14%) ▼|INTU258.05+0.28 (+0.11%) ▲|ISRG403.18+0.23 (+0.06%) ▲|JNJ239.08+7.79 (+3.37%) ▲|JPM334.14+2.66 (+0.80%) ▲|KO80.31+0.78 (+0.98%) ▲|LIN512.26-4.45 (-0.86%) ▼|LLY1,107.08+5.00 (+0.45%) ▲|LMT503.67+10.07 (+2.04%) ▲|LOW213.54-0.86 (-0.40%) ▼|LRCX371.33-38.21 (-9.33%) ▼|MA488.07+3.98 (+0.82%) ▲|MCD271.66+1.56 (+0.58%) ▲|MDLZ61.06+1.55 (+2.60%) ▲|MDT80.63+1.36 (+1.72%) ▲|META562.20-1.65 (-0.29%) ▼|MMM161.84-1.38 (-0.85%) ▼|MO71.61+2.10 (+3.02%) ▲|MRK119.60+4.12 (+3.57%) ▲|MS226.03-1.06 (-0.47%) ▼|MSFT373.94+6.60 (+1.80%) ▲|MU1,051.77-159.61 (-13.18%) ▼|NEE86.43+0.35 (+0.41%) ▲|NFLX72.82-0.06 (-0.08%) ▼|NKE42.38-0.81 (-1.88%) ▼|NOW95.94+2.93 (+3.15%) ▲|NVDA200.04-8.61 (-4.13%) ▼|ORCL165.16-9.91 (-5.66%) ▼|PEP142.05+1.34 (+0.95%) ▲|PFE24.72-0.36 (-1.44%) ▼|PG150.86+3.18 (+2.15%) ▲|PLTR116.70-2.80 (-2.34%) ▼|PM178.69+5.52 (+3.19%) ▲|QCOM204.13-17.77 (-8.01%) ▼|RTX186.39+4.56 (+2.51%) ▲|SBUX101.05+0.90 (+0.90%) ▲|SCHW93.17+1.14 (+1.24%) ▲|SO94.93+1.50 (+1.61%) ▲|SPG216.74+2.17 (+1.01%) ▲|T22.81+0.71 (+3.21%) ▲|TMO469.35+5.34 (+1.15%) ▲|TMUS184.57+4.51 (+2.50%) ▲|TSLA381.61-23.44 (-5.79%) ▼|TXN304.36-27.92 (-8.40%) ▼|UBER69.67-1.76 (-2.46%) ▼|UNH409.25+2.57 (+0.63%) ▲|UNP258.61-1.30 (-0.50%) ▼|UPS105.83-1.41 (-1.31%) ▼|USB60.05+1.37 (+2.33%) ▲|V328.48+1.88 (+0.58%) ▲|VZ46.73+1.37 (+3.02%) ▲|WFC84.13+0.29 (+0.35%) ▲|WMT119.42+2.24 (+1.91%) ▲|XOM139.73+1.26 (+0.91%) ▲|AAPL294.30-2.71 (-0.91%) ▼|ABBV234.76+4.75 (+2.07%) ▲|ABT90.53+2.70 (+3.07%) ▲|ACN127.01+2.18 (+1.75%) ▲|ADBE197.43+2.53 (+1.30%) ▲|AMAT585.88-54.30 (-8.48%) ▼|AMD519.85-31.78 (-5.76%) ▼|AMGN347.01+2.29 (+0.66%) ▲|AMT179.38+2.95 (+1.67%) ▲|AMZN234.11+1.32 (+0.57%) ▲|AVGO380.15-11.98 (-3.06%) ▼|AXP337.78-0.29 (-0.09%) ▼|BA216.71-4.12 (-1.87%) ▼|BAC57.91+0.54 (+0.94%) ▲|BKNG168.94+1.17 (+0.70%) ▲|BLK1,015.33-36.41 (-3.46%) ▼|BMY55.53+0.83 (+1.52%) ▲|BNY147.29+0.85 (+0.58%) ▲|BRK-B492.81+4.12 (+0.84%) ▲|C144.97-0.70 (-0.48%) ▼|CAT984.24-38.04 (-3.72%) ▼|CL91.43+2.76 (+3.11%) ▲|CMCSA22.80+0.48 (+2.15%) ▲|COF197.81-2.89 (-1.44%) ▼|COP109.97+0.27 (+0.25%) ▲|COST957.68+6.33 (+0.67%) ▲|CRM153.42+3.30 (+2.20%) ▲|CSCO121.15-0.38 (-0.31%) ▼|CVS101.57+0.27 (+0.27%) ▲|CVX175.98+0.92 (+0.53%) ▲|DE591.94-6.65 (-1.11%) ▼|DHR178.97+0.78 (+0.44%) ▲|DIS103.53+1.08 (+1.05%) ▲|DUK125.05+1.53 (+1.24%) ▲|EMR143.14-7.07 (-4.71%) ▼|FDX317.24-11.54 (-3.51%) ▼|GD350.34+6.98 (+2.03%) ▲|GE356.47+1.35 (+0.38%) ▲|GEV1,034.98-92.61 (-8.21%) ▼|GILD125.05+0.18 (+0.14%) ▲|GM78.95-1.48 (-1.84%) ▼|GOOG346.08-2.70 (-0.77%) ▼|GOOGL346.13-3.43 (-0.98%) ▼|GS1,094.44-11.93 (-1.08%) ▼|HD324.45-2.17 (-0.66%) ▼|HON222.37-5.74 (-2.52%) ▼|IBM264.94+12.72 (+5.04%) ▲|INTC132.28-8.66 (-6.14%) ▼|INTU258.05+0.28 (+0.11%) ▲|ISRG403.18+0.23 (+0.06%) ▲|JNJ239.08+7.79 (+3.37%) ▲|JPM334.14+2.66 (+0.80%) ▲|KO80.31+0.78 (+0.98%) ▲|LIN512.26-4.45 (-0.86%) ▼|LLY1,107.08+5.00 (+0.45%) ▲|LMT503.67+10.07 (+2.04%) ▲|LOW213.54-0.86 (-0.40%) ▼|LRCX371.33-38.21 (-9.33%) ▼|MA488.07+3.98 (+0.82%) ▲|MCD271.66+1.56 (+0.58%) ▲|MDLZ61.06+1.55 (+2.60%) ▲|MDT80.63+1.36 (+1.72%) ▲|META562.20-1.65 (-0.29%) ▼|MMM161.84-1.38 (-0.85%) ▼|MO71.61+2.10 (+3.02%) ▲|MRK119.60+4.12 (+3.57%) ▲|MS226.03-1.06 (-0.47%) ▼|MSFT373.94+6.60 (+1.80%) ▲|MU1,051.77-159.61 (-13.18%) ▼|NEE86.43+0.35 (+0.41%) ▲|NFLX72.82-0.06 (-0.08%) ▼|NKE42.38-0.81 (-1.88%) ▼|NOW95.94+2.93 (+3.15%) ▲|NVDA200.04-8.61 (-4.13%) ▼|ORCL165.16-9.91 (-5.66%) ▼|PEP142.05+1.34 (+0.95%) ▲|PFE24.72-0.36 (-1.44%) ▼|PG150.86+3.18 (+2.15%) ▲|PLTR116.70-2.80 (-2.34%) ▼|PM178.69+5.52 (+3.19%) ▲|QCOM204.13-17.77 (-8.01%) ▼|RTX186.39+4.56 (+2.51%) ▲|SBUX101.05+0.90 (+0.90%) ▲|SCHW93.17+1.14 (+1.24%) ▲|SO94.93+1.50 (+1.61%) ▲|SPG216.74+2.17 (+1.01%) ▲|T22.81+0.71 (+3.21%) ▲|TMO469.35+5.34 (+1.15%) ▲|TMUS184.57+4.51 (+2.50%) ▲|TSLA381.61-23.44 (-5.79%) ▼|TXN304.36-27.92 (-8.40%) ▼|UBER69.67-1.76 (-2.46%) ▼|UNH409.25+2.57 (+0.63%) ▲|UNP258.61-1.30 (-0.50%) ▼|UPS105.83-1.41 (-1.31%) ▼|USB60.05+1.37 (+2.33%) ▲|V328.48+1.88 (+0.58%) ▲|VZ46.73+1.37 (+3.02%) ▲|WFC84.13+0.29 (+0.35%) ▲|WMT119.42+2.24 (+1.91%) ▲|XOM139.73+1.26 (+0.91%) ▲|
18.9 C
New York
Wednesday, June 24, 2026

Tag: journal

newssourceFORcompanyinformationcontent1marketreleases

PRIORITIZE PROSTATE SCREENING–IT’S THE BEST DEFENSE AGAINST PROSTATE CANCER, SAYS PROCURE

SOMERSET, N.J., June 23, 2025 /PRNewswire/ -- ProCure Proton Therapy Center reminds area residents about the critical importance to men of prostate-specific antigen (PSA)...

Atrogi announces Cell paper highlighting transformative potential of muscle-targeted therapy in metabolic disease

Atrogi's breakthrough discovery enables chronic use of next-generation, highly selective β2-agonists for the first time in metabolic diseaseFirst-in-class oral therapy ATR-258 mimics the effects...

Atrogi announces Cell paper highlighting transformative potential of muscle-targeted therapy in metabolic disease

Atrogi's breakthrough discovery enables chronic use of next-generation, highly selective β2-agonists for the first time in metabolic diseaseFirst-in-class oral therapy ATR-258 mimics the effects...

Sana Biotechnology Announces Positive Six-Month Clinical Results from Type 1 Diabetes Study of Islet Cell Transplantation Without Immunosuppression

Groundbreaking First-in-Human Study Establishes Potential to Treat Type 1 Diabetes by Transplanting Insulin-Secreting Cells Without Immunosuppression

IMBRUVICA® (ibrutinib) reçoit un avis favorable du CHMP pour le traitement des patients atteints d’un lymphome à cellules du manteau (LCM) non préalablement traités...

En attendant la décision finale de la Commission européenne, le régime offre une nouvelle norme de soins pour les patients éligibles atteints d’LMC1,2

Nipocalimab showed greater sustained disease control versus approved FcRn blockers for generalised myasthenia gravis (gMG) at multiple timepoints over 24 weeks in newly published...

The ITC compared all published Phase 3 data of these treatments, leveraging longitudinal results, and findings reinforce the importance of consistent, sustained disease control in managing a chronic autoantibody disease like gMG

IMAAVY™ (nipocalimab-aahu) showed greater sustained disease control versus approved FcRn blockers for generalized myasthenia gravis (gMG) at multiple timepoints over 24 weeks in newly...

The ITC compared all published Phase 3 data of these treatments, leveraging longitudinal results, and findings reinforce the importance of consistent, sustained disease control...

Kanazawa University research: From hydration layers to nanoarchitectures: Water’s pivotal role in peptide organization on 2D nanomaterials

KANAZAWA, Japan, June 23, 2025 /PRNewswire/ -- Researchers at the Nano Life Science Institute (WPI-NanoLSI), Kanazawa University, report in Small, a weekly peer-reviewed scientific...

ITM and Debiopharm Announce First Patient Imaged in New Study Arm of Phase 1/2 Trial Evaluating ITM-94 as Diagnostic Agent for Clear Cell Renal...


Garching / Munich, Germany, and Lausanne, Switzerland - June 23, 2025 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company and Debiopharm, a Swiss-based, global biopharmaceutical company aiming to establish tomorrow’s standard-of-care to cure cancer and infectious diseases, today announced that the first patient was imaged in a new study arm of a five-part, Phase 1/2 clinical trial (formerly GaLuCi™) (NCT05706129) evaluating the theranostic pair ITM-94/ITM-91 for identification and treatment of patients who have unresectable, locally advanced or metastatic solid tumors. As a new component of a broad clinical development plan for ITM-91/ITM-94, Part D of the trial will evaluate the effectiveness of ITM-94 in classifying indeterminate renal mass as either ccRCC or non-cancerous.

New study published in Journal of Experimental Medicine reveals a CARMIL2 mutation with therapeutic antitumor potential

Press Release

AI Query Processing: Quantifying Carbon Footprint in Algorithmic Models

Artificial intelligence, particularly generative AI, is becoming integral to various aspects of daily life, from search engine optimization to automated email composition. However, the...

Everest Medicines Announces Official Publication of the Specifications for Antimicrobial Susceptibility Testing of Eravacycline (2025)

SHANGHAI, June 23, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing,...

Oral Semaglutide Significantly Improves Cardiovascular Outcomes in Individuals with Type 2 Diabetes

Oral formulation demonstrates comparable cardiovascular benefits to injectable GLP-1s CHICAGO, June 22, 2025 /PRNewswire/ -- A recent study found that oral semaglutide offers meaningful cardiovascular benefits...

Lilly’s once-weekly insulin efsitora alfa demonstrated A1C reduction and a safety profile consistent with daily insulin in multiple Phase 3 trials

Results from the fixed-dose QWINT-1 study, along with the QWINT-3 and QWINT-4 studies, reinforce efsitora's potential to simplify insulin management with weekly dosing Lilly plans...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsJournal

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers